

ASX ANNOUNCEMENT

DATE: 25 March 2020

VIRTUS HEALTH LIMITED (ASX: VRT)

COVID-19 IMPACT UPDATE

Virtus Health Limited (ASX "VRT") provides the following update on the impact of COVID-19.

Virtus continues to treat IVF patients in Australia in accordance with published guidelines from *The Fertility Society of Australia* ("FSA"). FSA has updated its statement of the COVID-19 response on 24th March 2020 as follows:

"The FSA recommends that, in the interest of public safety, patients who are planning to start fertility treatment consult with their treating specialist and discuss the appropriateness of postponing their treatment.

The FSA recognises that there may be medical circumstances where delaying treatment may not be advisable and treating specialists should advise their patients if there are medical grounds to commence treatment now."

Virtus supports the FSA position and recognises the seriousness of the COVID-19 crisis and the implications for health services. In the interest of public health safety, we encourage those of our patients who were planning to commence a treatment, to consider postponing fertility treatment and staying at home. Each patient should, however, discuss their own situation with their specialist.

There may be patients who, because of their particular medical circumstances, will request to continue treatment at this point. Virtus clinics will continue to provide services for those patients who have commenced treatment and those who are advised by their specialist to commence treatment.

The position outlined above aligns with the Government's announcement today that all elective surgery is to be suspended, other than category 1 and urgent category 2 cases. IVF cycles in stimulation are by definition category 1 therefore those patients who have commenced treatment can continue. All other patients are being advised to consult their specialist.

Non-IVF elective surgery in our day hospitals had already significantly reduced and will now only proceed in accordance with the Government's directive.

Management in all jurisdictions are implementing strategies and other initiatives to mitigate the anticipated revenue impacts and maintain cash flow and the company will provide further updates to the market.

This announcement is authorised by the board of directors of the company.

-ENDS-



Further information:

Kate Munnings

Group CEO
Virtus Health
+61 (0)419661117

Kyahn Williamson

Investor Relations
Buchan Consulting
+61 (0)3 9866 4722
kwilliamson@buchanwe.com.au

About Virtus Health Limited

Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful medical collaborations in the world. With 125 of the world's leading fertility specialists supported by over 1200 professional staff, we are the largest network and provider of fertility services in Australia and Ireland, with a growing international presence in the UK, Denmark and Singapore.